The latest European Society of Cardiology guidelines suggest that intravenous iron supplementation may prevent adverse outcomes, such as death due to anemia [29], and angiotensin receptor/neprilysin inhibitors reduce NT-proBNP levels and reverse ventricular remodeling [30]; both these interventions may benefit those with HF and AF. The gene discussed is NPPB; the disease is hydrops fetalis.